In lung cancer (LC), CD155 is expressed in 38–48% of cases [1, 7] and is correlated with advanced stage, pleural/vascular invasion, PD-L1 positivity [1], higher bronchoalveolar tumor ratio [8], and shorter survival outcomes [3]. This evidence concerns the gene PVR and lung carcinoma.